MedTrace Logo

Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers

NCT03440021 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2019-01-10

No results posted yet for this study

Summary

The aim of the present study is to investigate changes in neural activity (BOLD signal), as measured using fMRI, in brain areas associated with emotional and working memory during task performance after single-dose administration of a novel selective alpha2c adrenoceptor antagonist (ORM-12741) in healthy volunteers. Further, it will be explored whether ORM-12741 affects connectivity between brain areas in rest, as measured using fMRI, and cognitive performance in the sample under investigation.

Conditions

  • Healthy Volunteer

Interventions

DRUG

ORM-12741

Novel selective alpha2c adrenoceptor antagonist

DRUG

Placebo

Identical in appearance to experimental drug, not psycho-active

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    collaborator INDUSTRY

  • University of Oxford

    collaborator OTHER

  • University of Cape Town

    lead OTHER

Principal Investigators

  • Dan J. Stein, MD, PhD · University of Cape Town

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-26
Primary Completion
2018-12-05
Completion
2018-12-06

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03440021 on ClinicalTrials.gov